HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE AND SLOW THE RATE OF COGNITIVE

高剂量补充剂可减少同型半胱氨酸并减缓认知速度

• 批准号: 7606780
• 负责人: JOHN M RINGMAN
• 金额: $ 0.24万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-21 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606780
• 关键词: AD 5; Activities of Daily Living; Apolipoprotein E; Behavior; Clinical; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Dose; End Point; Folic Acid; Funding; Genotype; Grant; Homocysteine; Homocystine; Impaired cognition; Institution; Measures; Methylenetetrahydrofolate reductase (NADPH); Quality of life; Rate; Research; Research Personnel; Resources; Safety; Source; Supplementation; Time; United States National Institutes of Health; clinically significant

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary: 1. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of cognitive decline in subjects with AD Secondary: 2. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will slow the rate of clinical decline, as measured by the time to reach clinically significant end-points, in subjects with AD 3. Determine whether reduction of homocysteine levels with high-dose folic acid/B6/B12 supplementation will favorably influence measures of behavior, activities of daily living, global status, and quality of life in subjects with AD 4. Examine the influence of apolipoprotein E and methylenetetrahydrofolate reductase (MTHFR) genotype on homocysteine reduction in subjects with AD 5. Determine the safety and tolerability of long-term treatment of AD subjects with high-dose supplements

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： 初级： 1.确定高剂量叶酸/B6/B12补充剂降低同型半胱氨酸水平是否会减缓AD受试者的认知能力下降速度 中学： 2.确定高剂量叶酸/B6/B12补充剂降低同型半胱氨酸水平是否会减缓AD受试者的临床下降速度（通过达到临床显著终点的时间测量） 3.确定高剂量叶酸/B6/B12补充剂降低同型半胱氨酸水平是否会对AD受试者的行为、日常生活活动、总体状态和生活质量指标产生有利影响 4.检测AD患者载脂蛋白E和亚甲基四氢叶酸还原酶（MTHFR）基因型对同型半胱氨酸降低的影响 5.确定AD受试者接受高剂量补充剂长期治疗的安全性和耐受性